News

In this interview, Susan Kellogg-Spadt, Ph.D., the director of female sexual medicine at the Center for Pelvic Medicine at Academic Urology of PA, discusses common menopausal sexual issues and how the culture around ageism and taboo is changing.

A budget model analysis finds that biosimilars for Prolia and Xgeva could provide cost savings for health plans.

A national survey of 157 patients with non-small cell lung cancer found that all groups prioritized extending life, but treatment preferences, including concerns about side effects and quality-of-life tradeoffs, differed across racial and ethnic groups.

AI’s very design encourages a small number of users to go down delusional rabbit holes, researchers argue in a preprint article.

In lupus patients, latent Epstein-Barr virus can reprogram B cells and send the body’s immune response into overdrive, resulting in widespread inflammation.

Drug and hospital prices are top employer healthcare concerns as costs rise, but some employers are unable to access their data, finds a survey by the National Alliance of Healthcare Purchaser Coalitions.

World AIDS Day highlights ongoing challenges in HIV prevention and treatment, urging renewed commitment to end the epidemic and support affected communities.

Drug approvals this year have reflected the trend in clinical development of biologics shifting from intravenous to subcutaneous administration, offering shorter injection times, home use, and cost savings for cancer, Alzheimer’s, and inflammatory diseases.

A new report reveals the heavy personal and economic toll of MS and recommends more complete, patient focused approaches to measuring and managing the disease.

Kamuvudines are a new class of drugs that are derived from the anti-HIV nucleoside reverse transcriptase inhibitors. They are designed to inhibit the inflammasome, part of the innate immune system that is triggered in geographic atrophy.

CMS has released the negotiated prices for the second set of drugs for Medicare Part D through the Inflation Reduction Act. Discounts range from 38% for Austedo and Austedo XR to 85% for Janumet and Janumet XR.

Ralph Abraham's appointment as CDC's principal deputy director raises concerns over vaccine trust and public health amid political pressures and misinformation.

Telehealth mostly replaces in-person visits, with a 74% substitution rate, indicating lower federal costs and sustained value beyond the pandemic.

Itvisma is a one-time gene therapy approved for both children and adults with spinal muscular atrophy. It will be available in December.

A provision in the One Big Beautiful Bill delays or exempts high-spending medications with orphan indications from Medicare drug price negotiations.

A new blood test and app combination enhances tuberculosis screening in China, enabling early detection and cost-effective solutions in resource-limited areas.

ASTRO's new guidelines enhance radiation therapy strategies for gastric cancer, improving treatment outcomes and patient care across various stages of the disease.

Nicotine dependency is a worldwide health threat, especially for HIV patients, who are more likely to smoke and to have health complications than healthy patients.

Beginning in January 2026, Optum Rx is removing reauthorizations for two new drug classes: hormone therapies and knee osteoarthritis injectables.

Here’s what you missed this week on Managed Healthcare Executive.

Public health experts express concern over the CDC's revised vaccine-autism webpage, warning it may fuel mistrust and confusion about vaccine safety.

GLP-1 receptor agonists significantly lower five-year mortality in highly obese colon cancer patients, highlighting potential benefits beyond weight loss and inflammation reduction.

This year marks the fifth consecutive year Independence Blue Shield has received high marks for their Medicare plans.

A new report says complications such as severe encephalitis and Ramsay Hunt Syndrome are among the reasons people with shingles have extended hospital stays.

A pilot program limiting the patient co-pay to $50 could burden Part D plans, depending on whether manufacturers discount their prices — and by how much.

The patch measures distinct electrical patterns, which indicates how easily electrical signals pass through living tissue. Cancerous areas have different electrical properties than healthy skin.